Abstract
The accumulation of amyloid-beta and concomitant oxidative stress are major pathogenic events in Alzheimer's disease. Indole-3-propionic acid (IPA, OXIGON) is a potent anti-oxidant devoid of pro-oxidant activity. IPA has been demonstrated to be an inhibitor of beta-amyloid fibril formation and to be a potent neuroprotectant against a variety of oxidotoxins. This review will summarize the known properties of IPA and outline the rationale behind its selection as a potential disease-modifying therapy for Alzheimer's disease.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
-
Review
MeSH terms
-
Alzheimer Disease / drug therapy*
-
Alzheimer Disease / metabolism
-
Amyloid beta-Peptides / drug effects
-
Amyloid beta-Peptides / metabolism
-
Animals
-
Antioxidants / therapeutic use*
-
Humans
-
Indoles / pharmacology*
-
Indoles / therapeutic use
-
Neurofibrillary Tangles / drug effects
-
Neurofibrillary Tangles / metabolism
-
Neuroprotective Agents / pharmacology*
-
Neuroprotective Agents / therapeutic use
-
Oxidative Stress / drug effects
Substances
-
Amyloid beta-Peptides
-
Antioxidants
-
Indoles
-
Neuroprotective Agents
-
indolepropionic acid